Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost — First Eye Disorder Patient Could Be Treated Within 90 Days
Ocugen is building an international pathway for OCU400 ahead of key Phase 3 data and a planned U.S. regulatory filing next year. Ocugen aims to treat the first retinitis pigmentosa patient in the Bahamas within 90 days, subject to full regulatory approval. OCU400 is in a Phase 3 study, with topline data expected in Q1 … Read more